Rankings
▼
Calendar
ALXO Q3 2024 Earnings — ALX Oncology Holdings Inc. Revenue & Financial Results | Market Cap Arena
ALXO
ALX Oncology Holdings Inc.
$112M
Q3 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$33M
Net Income
-$31M
EPS (Diluted)
$-0.58
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$25M
Free Cash Flow
-$26M
Stock-Based Comp.
$7M
Balance Sheet
Total Assets
$186M
Total Liabilities
$49M
Stockholders' Equity
$137M
Cash & Equivalents
$16M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$33M
-$53M
+38.9%
Net Income
-$31M
-$51M
+39.8%
← FY 2024
All Quarters
Q4 2024 →